Halozyme Therapeutics - HALO Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.

9 equities research analysts have issued 12 month target prices for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $68.00. On average, they predict the company's share price to reach $56.33 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.

Halozyme Therapeutics' stock was trading at $56.90 at the beginning of 2023. Since then, HALO shares have decreased by 32.9% and is now trading at $38.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our HALO earnings forecast.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the consensus estimate of $0.42 by $1.06. The biopharmaceutical company had revenue of $115.83 million for the quarter, compared to analysts' expectations of $101.94 million. Halozyme Therapeutics had a net margin of 30.62% and a trailing twelve-month return on equity of 141.30%. During the same quarter last year, the business posted $0.25 EPS.

ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Active ETF (FFND), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco DWA Healthcare Momentum ETF (PTH), Goldman Sachs Future Health Care Equity ETF (GDOC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and WisdomTree U.S. Growth & Momentum Fund (WGRO).

Halozyme Therapeutics updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided earnings per share (EPS) guidance of $2.50-$2.65 for the period, compared to the consensus earnings per share estimate of $2.78. The company issued revenue guidance of $815.00 million-$845.00 million, compared to the consensus revenue estimate of $868.12 million.

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HALO stock can currently be purchased for approximately $38.19.

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.17 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.45 on an earnings per share basis.

The company employs 145 workers across the globe.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.